U.S. FDA approves Pfizer’s Cibinqo (abrocitinib) for adults with moderate to severe atopic dermatitis


14 January 2022 - Cibinqo is a once daily oral treatment with proven efficacy to manage symptoms for adults who have not yet found relief with current options.

Pfizer announced today that the U.S. FDA approved Cinbinqo (abrocitinib), an oral, once daily, Janus kinase 1 inhibitor, for the treatment of adults living with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US